Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C9H13NO2 |
Molecular Weight | 167.205 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CNC[C@H](O)C1=CC(O)=CC=C1
InChI
InChIKey=SONNWYBIRXJNDC-VIFPVBQESA-N
InChI=1S/C9H13NO2/c1-10-6-9(12)7-3-2-4-8(11)5-7/h2-5,9-12H,6H2,1H3/t9-/m0/s1
Molecular Formula | C9H13NO2 |
Molecular Weight | 167.205 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
DescriptionSources: http://www.drugbank.ca/drugs/DB00388Curator's Comment: Description was created based on several sources, including
http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/204300lbl.pdf and
https://www.drugs.com/pro/phenylephrine-and-chlorpheniramine-tablets.html
Sources: http://www.drugbank.ca/drugs/DB00388
Curator's Comment: Description was created based on several sources, including
http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/204300lbl.pdf and
https://www.drugs.com/pro/phenylephrine-and-chlorpheniramine-tablets.html
Phenylephrine is a powerful vasoconstrictor. It is used as a nasal decongestant and cardiotonic agent. Phenylephrine is a postsynaptic α1-receptor agonist with little effect on β-receptors of the heart. Parenteral administration of phenylephrine causes a rise in systolic and diastolic pressures, a slight decrease in cardiac output, and a considerable increase in peripheral resistance; most vascular beds are constricted, and renal, splanchnic, cutaneous, and limb blood flows are reduced while coronary blood flow is increased. Phenelephrine also causes pulmonary vessel constriction and subsequent increase in pulmonary arterial pressure. Vasoconstriction in the mucosa of the respiratory tract leads to decreased edema and increased drainage of sinus cavities. In general, α1-adrenergic receptors mediate contraction and hypertrophic growth of smooth muscle cells. α1-receptors are 7-transmembrane domain receptors coupled to G proteins, Gq/11. Three α1-receptor subtypes, which share approximately 75% homology in their transmembrane domains, have been identified: α1A (chromosome 8), α1B (chromosome 5), and α1D (chromosome 20). Phenylephrine appears to act similarly on all three receptor subtypes. All three receptor subtypes appear to be involved in maintaining vascular tone. The α1A-receptor maintains basal vascular tone while the α1B-receptor mediates the vasocontrictory effects of exogenous α1-agonists. Activation of the α1-receptor activates Gq-proteins, which results in intracellular stimulation of phospholipases C, A2, and D. This results in mobilization of Ca2+ from intracellular stores, activation of mitogen-activated kinase and PI3 kinase pathways and subsequent vasoconstriction. Phenylephrine produces its local and systemic actions by acting on α1-adrenergic receptors peripheral vascular smooth muscle. Stimulation of the α1-adrenergic receptors results in contraction arteriolar smooth muscle in the periphery. Phenylephrine decreases nasal congestion by acting on α1-adrenergic receptors in the arterioles of the nasal mucosa to produce constriction; this leads to decreased edema and increased drainage of the sinus cavities. Phenylephrine is mainly used to treat nasal congestion, but may also be useful in treating hypotension and shock, hypotension during spinal anaesthesia, prolongation of spinal anaesthesia, paroxysmal supraventricular tachycardia, symptomatic relief of external or internal hemorrhoids, and to increase blood pressure as an aid in the diagnosis of heart murmurs.
CNS Activity
Sources: https://www.ncbi.nlm.nih.gov/pubmed/22391890
Curator's Comment: Phenylephrine does not cross the blood–brain barrier
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL229 Sources: http://www.drugbank.ca/drugs/DB00388 |
55.0 nM [EC50] | ||
Target ID: CHEMBL232 Sources: https://www.ncbi.nlm.nih.gov/pubmed/25813897 |
5.9 nM [EC50] | ||
Target ID: CHEMBL326 Sources: https://www.ncbi.nlm.nih.gov/pubmed/8831777 |
154.88 nM [EC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | VAZCULEP Approved UseVAZCULEP (phenylephrine hydrochloride) is indicated for the treatment of clinically important
hypotension resulting primarily from vasodilation in the setting of anesthesia. Launch Date-5.05007997E11 |
|||
Diagnostic | Phenylephrine Hydrochloride Ophthalmic Solution Approved UseIndicated to dilate the pupil Launch Date-9.7839363E11 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
2959 pg/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/26267590 |
20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered: |
PHENYLEPHRINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
4492 pg/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/26267590 |
30 mg single, oral dose: 30 mg route of administration: Oral experiment type: SINGLE co-administered: |
PHENYLEPHRINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
1354 pg/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/26267590 |
10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered: |
PHENYLEPHRINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
2346 pg × h/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/26267590 |
20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered: |
PHENYLEPHRINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
3900 pg × h/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/26267590 |
30 mg single, oral dose: 30 mg route of administration: Oral experiment type: SINGLE co-administered: |
PHENYLEPHRINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
955.8 pg × h/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/26267590 |
10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered: |
PHENYLEPHRINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
1.93 h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/26267590 |
20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered: |
PHENYLEPHRINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
1.64 h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/26267590 |
30 mg single, oral dose: 30 mg route of administration: Oral experiment type: SINGLE co-administered: |
PHENYLEPHRINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
1.89 h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/26267590 |
10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered: |
PHENYLEPHRINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
Doses
Dose | Population | Adverse events |
---|---|---|
10 mg 1 times / day multiple, oral Dose: 10 mg, 1 times / day Route: oral Route: multiple Dose: 10 mg, 1 times / day Sources: |
unhealthy, 34 years n = 1 Health Status: unhealthy Age Group: 34 years Sex: M Population Size: 1 Sources: |
Disc. AE: Ischemic colitis... AEs leading to discontinuation/dose reduction: Ischemic colitis (acute) Sources: |
40 mg 6 times / day multiple, oral Highest studied dose Dose: 40 mg, 6 times / day Route: oral Route: multiple Dose: 40 mg, 6 times / day Sources: |
unhealthy, 37.5 years (range: 19.0 - 77.0 years) n = 112 Health Status: unhealthy Condition: Seasonal Allergic Rhinitis Age Group: 37.5 years (range: 19.0 - 77.0 years) Sex: M+F Population Size: 112 Sources: |
Disc. AE: Chest pain, Jaw pain... Other AEs: Nervous system disorders, Headache... AEs leading to discontinuation/dose reduction: Chest pain (1 patient) Other AEs:Jaw pain (1 patient) Nervous system disorders (3.6%) Sources: Headache (2.7%) Gastrointestinal disorders (8%) Dry mouth (2.7%) Nausea (3.6%) |
10 % 3 times / day multiple, ophthalmic Recommended Dose: 10 %, 3 times / day Route: ophthalmic Route: multiple Dose: 10 %, 3 times / day Sources: |
healthy, > 1 year Health Status: healthy Age Group: > 1 year Sources: |
Other AEs: Eye pain, Blurred vision... Other AEs: Eye pain Sources: Blurred vision Photophobia Allergic conjunctivitis |
250 ug single, intravenous Recommended Dose: 250 ug Route: intravenous Route: single Dose: 250 ug Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sources: |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Ischemic colitis | acute Disc. AE |
10 mg 1 times / day multiple, oral Dose: 10 mg, 1 times / day Route: oral Route: multiple Dose: 10 mg, 1 times / day Sources: |
unhealthy, 34 years n = 1 Health Status: unhealthy Age Group: 34 years Sex: M Population Size: 1 Sources: |
Chest pain | 1 patient Disc. AE |
40 mg 6 times / day multiple, oral Highest studied dose Dose: 40 mg, 6 times / day Route: oral Route: multiple Dose: 40 mg, 6 times / day Sources: |
unhealthy, 37.5 years (range: 19.0 - 77.0 years) n = 112 Health Status: unhealthy Condition: Seasonal Allergic Rhinitis Age Group: 37.5 years (range: 19.0 - 77.0 years) Sex: M+F Population Size: 112 Sources: |
Jaw pain | 1 patient Disc. AE |
40 mg 6 times / day multiple, oral Highest studied dose Dose: 40 mg, 6 times / day Route: oral Route: multiple Dose: 40 mg, 6 times / day Sources: |
unhealthy, 37.5 years (range: 19.0 - 77.0 years) n = 112 Health Status: unhealthy Condition: Seasonal Allergic Rhinitis Age Group: 37.5 years (range: 19.0 - 77.0 years) Sex: M+F Population Size: 112 Sources: |
Dry mouth | 2.7% | 40 mg 6 times / day multiple, oral Highest studied dose Dose: 40 mg, 6 times / day Route: oral Route: multiple Dose: 40 mg, 6 times / day Sources: |
unhealthy, 37.5 years (range: 19.0 - 77.0 years) n = 112 Health Status: unhealthy Condition: Seasonal Allergic Rhinitis Age Group: 37.5 years (range: 19.0 - 77.0 years) Sex: M+F Population Size: 112 Sources: |
Headache | 2.7% | 40 mg 6 times / day multiple, oral Highest studied dose Dose: 40 mg, 6 times / day Route: oral Route: multiple Dose: 40 mg, 6 times / day Sources: |
unhealthy, 37.5 years (range: 19.0 - 77.0 years) n = 112 Health Status: unhealthy Condition: Seasonal Allergic Rhinitis Age Group: 37.5 years (range: 19.0 - 77.0 years) Sex: M+F Population Size: 112 Sources: |
Nausea | 3.6% | 40 mg 6 times / day multiple, oral Highest studied dose Dose: 40 mg, 6 times / day Route: oral Route: multiple Dose: 40 mg, 6 times / day Sources: |
unhealthy, 37.5 years (range: 19.0 - 77.0 years) n = 112 Health Status: unhealthy Condition: Seasonal Allergic Rhinitis Age Group: 37.5 years (range: 19.0 - 77.0 years) Sex: M+F Population Size: 112 Sources: |
Nervous system disorders | 3.6% | 40 mg 6 times / day multiple, oral Highest studied dose Dose: 40 mg, 6 times / day Route: oral Route: multiple Dose: 40 mg, 6 times / day Sources: |
unhealthy, 37.5 years (range: 19.0 - 77.0 years) n = 112 Health Status: unhealthy Condition: Seasonal Allergic Rhinitis Age Group: 37.5 years (range: 19.0 - 77.0 years) Sex: M+F Population Size: 112 Sources: |
Gastrointestinal disorders | 8% | 40 mg 6 times / day multiple, oral Highest studied dose Dose: 40 mg, 6 times / day Route: oral Route: multiple Dose: 40 mg, 6 times / day Sources: |
unhealthy, 37.5 years (range: 19.0 - 77.0 years) n = 112 Health Status: unhealthy Condition: Seasonal Allergic Rhinitis Age Group: 37.5 years (range: 19.0 - 77.0 years) Sex: M+F Population Size: 112 Sources: |
Allergic conjunctivitis | 10 % 3 times / day multiple, ophthalmic Recommended Dose: 10 %, 3 times / day Route: ophthalmic Route: multiple Dose: 10 %, 3 times / day Sources: |
healthy, > 1 year Health Status: healthy Age Group: > 1 year Sources: |
|
Blurred vision | 10 % 3 times / day multiple, ophthalmic Recommended Dose: 10 %, 3 times / day Route: ophthalmic Route: multiple Dose: 10 %, 3 times / day Sources: |
healthy, > 1 year Health Status: healthy Age Group: > 1 year Sources: |
|
Eye pain | 10 % 3 times / day multiple, ophthalmic Recommended Dose: 10 %, 3 times / day Route: ophthalmic Route: multiple Dose: 10 %, 3 times / day Sources: |
healthy, > 1 year Health Status: healthy Age Group: > 1 year Sources: |
|
Photophobia | 10 % 3 times / day multiple, ophthalmic Recommended Dose: 10 %, 3 times / day Route: ophthalmic Route: multiple Dose: 10 %, 3 times / day Sources: |
healthy, > 1 year Health Status: healthy Age Group: > 1 year Sources: |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Other Inhibitor | Other Substrate | Other Inducer |
---|---|---|
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Sources: https://pubmed.ncbi.nlm.nih.gov/16510159/ Page: 10.0 |
yes |
PubMed
Title | Date | PubMed |
---|---|---|
Altered baroreflex control of heart rate in bradykinin B2-receptor knockout mice. | 1999 Dec |
|
[An unusual episode of angina]. | 1999 Mar |
|
Phosphorylation of elk-1 by MEK/ERK pathway is necessary for c-fos gene activation during cardiac myocyte hypertrophy. | 2000 Aug |
|
Purinergic and adrenergic agonists synergize in stimulating vasopressin and oxytocin release. | 2000 Dec 1 |
|
Neuropeptide Y (NPY) potentiates phenylephrine-induced mitogen-activated protein kinase activation in primary cardiomyocytes via NPY Y5 receptors. | 2000 Feb 15 |
|
Bupivacaine inhibits baroreflex control of heart rate in conscious rats. | 2000 Jan |
|
Fine structure and plasticity of barosensitive neurons in the nucleus of solitary tract. | 2000 Jul 3 |
|
Requirement of activation of the extracellular signal-regulated kinase cascade in myocardial cell hypertrophy. | 2000 Jun |
|
Mesenteric dysfunction after cardiopulmonary bypass: role of complement C5a. | 2000 Mar |
|
Gene transfer of endothelial nitric oxide synthase improves relaxation of carotid arteries from diabetic rabbits. | 2000 Mar 7 |
|
Heparin-mediated hypotension associated with cardiac surgery. | 2000 Sep |
|
Effects of salt intake and angiotensin II on vascular reactivity to endothelin-1. | 2001 Feb |
|
Reflex cardiovascular responses originating in exercising muscles of mice. | 2001 Feb |
|
Smooth muscle-targeted overexpression of insulin-like growth factor I results in enhanced vascular contractility. | 2001 Feb |
|
Nitric oxide-mediated arteriolar dilation after endothelial deformation. | 2001 Feb |
|
Vascular NAD(P)H oxidase is distinct from the phagocytic enzyme and modulates vascular reactivity control. | 2001 Feb |
|
Regulation of mitogen-activated protein kinases in cardiac myocytes through the small G protein Rac1. | 2001 Feb |
|
Interaction of rapid nongenomic cardiovascular aldosterone effects with the adrenergic system. | 2001 Feb |
|
Heat, but not mechanical hyperalgesia, following adrenergic injections in normal human skin. | 2001 Feb 1 |
|
The transient receptor potential protein homologue TRP6 is the essential component of vascular alpha(1)-adrenoceptor-activated Ca(2+)-permeable cation channel. | 2001 Feb 16 |
|
Ras regulates NFAT3 activity in cardiac myocytes. | 2001 Feb 2 |
|
Nitric oxide contributes to vascular smooth muscle relaxation in contracting fast-twitch muscles. | 2001 Feb 7 |
|
Extracellular calcium-sensing receptor is expressed in rat hepatocytes. coupling to intracellular calcium mobilization and stimulation of bile flow. | 2001 Feb 9 |
|
Detection and characterization of cholinergic oscillatory control in the forehead microvasculature in response to systemic alpha-agonist infusion in healthy volunteers. | 2001 Jan |
|
A N-terminal PTHrP peptide fragment void of a PTH/PTHrP-receptor binding domain activates cardiac ET(A) receptors. | 2001 Jan |
|
Activity of cardiorespiratory networks revealed by transsynaptic virus expressing GFP. | 2001 Jan |
|
Involvement of Ca2+ -activated K+ channels in ginsenosides-induced aortic relaxation in rats. | 2001 Jan |
|
Effect of dietary vitamin E supplementation on vascular reactivity of thoracic aorta in streptozotocin-diabetic rats. | 2001 Jan |
|
Increased dilator response to heptanol and octanol in aorta from DOCA-salt-hypertensive rats. | 2001 Jan |
|
In vivo measurement of pulsewave velocity in small vessels using intravascular MR. | 2001 Jan |
|
Exercise attenuates alpha-adrenergic-receptor responsiveness in skeletal muscle vasculature. | 2001 Jan |
|
Catecholamine responses to alpha-adrenergic blockade during exercise in women acutely exposed to altitude. | 2001 Jan |
|
Should the angiotensin II antagonists be discontinued before surgery? | 2001 Jan |
|
Effects of acute and chronic hypertension on the labyrinthine barriers in rat. | 2001 Jan |
|
CYP4A1 antisense oligonucleotide reduces mesenteric vascular reactivity and blood pressure in SHR. | 2001 Jan |
|
Acute hypertension inhibits thirst stimulated by ANG II, hyperosmolality, or hypovolemia in rats. | 2001 Jan |
|
[Ca(2+)](i) signaling in renal arterial smooth muscle cells of pregnant rat is enhanced during inhibition of NOS. | 2001 Jan |
|
Endothelin and nitric oxide mediate reduced myogenic reactivity of small renal arteries from pregnant rats. | 2001 Jan |
|
Inducible and neuronal nitric oxide synthase involvement in lipopolysaccharide-induced sphincteric dysfunction. | 2001 Jan |
|
Gender-related distinctions in protein kinase C activity in rat vascular smooth muscle. | 2001 Jan |
|
Novel site-specific chemical delivery system as a potential mydriatic agent: formation of phenylephrine in the iris-ciliary body from phenylephrone chemical delivery systems. | 2001 Jan |
|
Receptor reserve analysis of the human alpha(2C)-adrenoceptor using. | 2001 Jan 12 |
|
In vivo regulation of Na/Ca exchanger expression by adrenergic effectors. | 2001 Mar |
|
Regulation of slow wave frequency by IP(3)-sensitive calcium release in the murine small intestine. | 2001 Mar |
|
EDHF contributes to strain-related differences in pulmonary arterial relaxation in rats. | 2001 Mar |
Sample Use Guides
In Vivo Use Guide
Curator's Comment: Also used as Ophthalmic Solution or oral tablets
http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/203510s000lbl.pdf
https://www.drugs.com/dosage/chlorpheniramine-phenylephrine.html
VAZCULEP (phenylephrine hydrochloride) Injection, 10 mg/mL, is injected
intravenously either as a bolus or in a dilute solution as a continuous infusion.
Dilute before administration.
Dosing for treatment of hypotension during anesthesia
Bolus intravenous injection: 40 mcg to 100 mcg every 1-2 minutes as
needed, not to exceed 200 mcg.
Intravenous infusion: 10 mcg/min to 35 mcg/min, titrating to effect, not to
exceed 200 mcg/min.
Route of Administration:
Intravenous
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/26406609
The hypertrophic phenotype of neonatal rat cardiomyocyte cultures (cardiomyocyte size, sarcomeric organization, total protein synthesis, c-fos expression) mediated by phenylephrine (10 uM) was counteracted by the selective A1 receptor agonist
Substance Class |
Chemical
Created
by
admin
on
Edited
Wed Jul 05 22:38:33 UTC 2023
by
admin
on
Wed Jul 05 22:38:33 UTC 2023
|
Record UNII |
1WS297W6MV
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
LIVERTOX |
773
Created by
admin on Wed Jul 05 22:38:33 UTC 2023 , Edited by admin on Wed Jul 05 22:38:33 UTC 2023
|
||
|
WHO-VATC |
QR01BA03
Created by
admin on Wed Jul 05 22:38:33 UTC 2023 , Edited by admin on Wed Jul 05 22:38:33 UTC 2023
|
||
|
WHO-VATC |
QS01FB01
Created by
admin on Wed Jul 05 22:38:33 UTC 2023 , Edited by admin on Wed Jul 05 22:38:33 UTC 2023
|
||
|
WHO-VATC |
QR01AA04
Created by
admin on Wed Jul 05 22:38:33 UTC 2023 , Edited by admin on Wed Jul 05 22:38:33 UTC 2023
|
||
|
WHO-VATC |
QC01CA06
Created by
admin on Wed Jul 05 22:38:33 UTC 2023 , Edited by admin on Wed Jul 05 22:38:33 UTC 2023
|
||
|
WHO-ATC |
R01BA03
Created by
admin on Wed Jul 05 22:38:33 UTC 2023 , Edited by admin on Wed Jul 05 22:38:33 UTC 2023
|
||
|
WHO-ATC |
R01AB01
Created by
admin on Wed Jul 05 22:38:33 UTC 2023 , Edited by admin on Wed Jul 05 22:38:33 UTC 2023
|
||
|
WHO-ATC |
R01BA53
Created by
admin on Wed Jul 05 22:38:33 UTC 2023 , Edited by admin on Wed Jul 05 22:38:33 UTC 2023
|
||
|
WHO-VATC |
QS01GA55
Created by
admin on Wed Jul 05 22:38:33 UTC 2023 , Edited by admin on Wed Jul 05 22:38:33 UTC 2023
|
||
|
WHO-ATC |
C01CA06
Created by
admin on Wed Jul 05 22:38:33 UTC 2023 , Edited by admin on Wed Jul 05 22:38:33 UTC 2023
|
||
|
WHO-ATC |
S01BB01
Created by
admin on Wed Jul 05 22:38:33 UTC 2023 , Edited by admin on Wed Jul 05 22:38:33 UTC 2023
|
||
|
WHO-VATC |
QS01GA05
Created by
admin on Wed Jul 05 22:38:33 UTC 2023 , Edited by admin on Wed Jul 05 22:38:33 UTC 2023
|
||
|
WHO-VATC |
QR01AB01
Created by
admin on Wed Jul 05 22:38:33 UTC 2023 , Edited by admin on Wed Jul 05 22:38:33 UTC 2023
|
||
|
WHO-ATC |
S01FB51
Created by
admin on Wed Jul 05 22:38:33 UTC 2023 , Edited by admin on Wed Jul 05 22:38:33 UTC 2023
|
||
|
WHO-ATC |
S01FB01
Created by
admin on Wed Jul 05 22:38:33 UTC 2023 , Edited by admin on Wed Jul 05 22:38:33 UTC 2023
|
||
|
FDA ORPHAN DRUG |
147201
Created by
admin on Wed Jul 05 22:38:33 UTC 2023 , Edited by admin on Wed Jul 05 22:38:33 UTC 2023
|
||
|
WHO-VATC |
QR01BA53
Created by
admin on Wed Jul 05 22:38:33 UTC 2023 , Edited by admin on Wed Jul 05 22:38:33 UTC 2023
|
||
|
NCI_THESAURUS |
C29709
Created by
admin on Wed Jul 05 22:38:33 UTC 2023 , Edited by admin on Wed Jul 05 22:38:33 UTC 2023
|
||
|
WHO-ATC |
S01GA55
Created by
admin on Wed Jul 05 22:38:33 UTC 2023 , Edited by admin on Wed Jul 05 22:38:33 UTC 2023
|
||
|
NDF-RT |
N0000186105
Created by
admin on Wed Jul 05 22:38:33 UTC 2023 , Edited by admin on Wed Jul 05 22:38:33 UTC 2023
|
||
|
WHO-ATC |
R01AA04
Created by
admin on Wed Jul 05 22:38:33 UTC 2023 , Edited by admin on Wed Jul 05 22:38:33 UTC 2023
|
||
|
WHO-ATC |
S01GA05
Created by
admin on Wed Jul 05 22:38:33 UTC 2023 , Edited by admin on Wed Jul 05 22:38:33 UTC 2023
|
||
|
FDA ORPHAN DRUG |
359011
Created by
admin on Wed Jul 05 22:38:33 UTC 2023 , Edited by admin on Wed Jul 05 22:38:33 UTC 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
C62067
Created by
admin on Wed Jul 05 22:38:33 UTC 2023 , Edited by admin on Wed Jul 05 22:38:33 UTC 2023
|
PRIMARY | |||
|
59-42-7
Created by
admin on Wed Jul 05 22:38:33 UTC 2023 , Edited by admin on Wed Jul 05 22:38:33 UTC 2023
|
PRIMARY | |||
|
8163
Created by
admin on Wed Jul 05 22:38:33 UTC 2023 , Edited by admin on Wed Jul 05 22:38:33 UTC 2023
|
PRIMARY | |||
|
D010656
Created by
admin on Wed Jul 05 22:38:33 UTC 2023 , Edited by admin on Wed Jul 05 22:38:33 UTC 2023
|
PRIMARY | |||
|
CHEMBL1215
Created by
admin on Wed Jul 05 22:38:33 UTC 2023 , Edited by admin on Wed Jul 05 22:38:33 UTC 2023
|
PRIMARY | |||
|
325517
Created by
admin on Wed Jul 05 22:38:33 UTC 2023 , Edited by admin on Wed Jul 05 22:38:33 UTC 2023
|
ALTERNATIVE | |||
|
1WS297W6MV
Created by
admin on Wed Jul 05 22:38:33 UTC 2023 , Edited by admin on Wed Jul 05 22:38:33 UTC 2023
|
PRIMARY | |||
|
8093
Created by
admin on Wed Jul 05 22:38:33 UTC 2023 , Edited by admin on Wed Jul 05 22:38:33 UTC 2023
|
PRIMARY | |||
|
DTXSID9023465
Created by
admin on Wed Jul 05 22:38:33 UTC 2023 , Edited by admin on Wed Jul 05 22:38:33 UTC 2023
|
PRIMARY | |||
|
485
Created by
admin on Wed Jul 05 22:38:33 UTC 2023 , Edited by admin on Wed Jul 05 22:38:33 UTC 2023
|
PRIMARY | |||
|
SUB09788MIG
Created by
admin on Wed Jul 05 22:38:33 UTC 2023 , Edited by admin on Wed Jul 05 22:38:33 UTC 2023
|
PRIMARY | |||
|
3383
Created by
admin on Wed Jul 05 22:38:33 UTC 2023 , Edited by admin on Wed Jul 05 22:38:33 UTC 2023
|
PRIMARY | |||
|
DB00388
Created by
admin on Wed Jul 05 22:38:33 UTC 2023 , Edited by admin on Wed Jul 05 22:38:33 UTC 2023
|
PRIMARY | |||
|
Phenylephrine
Created by
admin on Wed Jul 05 22:38:33 UTC 2023 , Edited by admin on Wed Jul 05 22:38:33 UTC 2023
|
PRIMARY | |||
|
6041
Created by
admin on Wed Jul 05 22:38:33 UTC 2023 , Edited by admin on Wed Jul 05 22:38:33 UTC 2023
|
PRIMARY | |||
|
200-424-8
Created by
admin on Wed Jul 05 22:38:33 UTC 2023 , Edited by admin on Wed Jul 05 22:38:33 UTC 2023
|
PRIMARY | |||
|
2146
Created by
admin on Wed Jul 05 22:38:33 UTC 2023 , Edited by admin on Wed Jul 05 22:38:33 UTC 2023
|
PRIMARY | |||
|
N0000009917
Created by
admin on Wed Jul 05 22:38:33 UTC 2023 , Edited by admin on Wed Jul 05 22:38:33 UTC 2023
|
PRIMARY | Adrenergic alpha1-Agonists [MoA] | ||
|
1WS297W6MV
Created by
admin on Wed Jul 05 22:38:33 UTC 2023 , Edited by admin on Wed Jul 05 22:38:33 UTC 2023
|
PRIMARY | |||
|
M8668
Created by
admin on Wed Jul 05 22:38:33 UTC 2023 , Edited by admin on Wed Jul 05 22:38:33 UTC 2023
|
PRIMARY | Merck Index | ||
|
100000088260
Created by
admin on Wed Jul 05 22:38:33 UTC 2023 , Edited by admin on Wed Jul 05 22:38:33 UTC 2023
|
PRIMARY | |||
|
PHENYLEPHRINE
Created by
admin on Wed Jul 05 22:38:33 UTC 2023 , Edited by admin on Wed Jul 05 22:38:33 UTC 2023
|
PRIMARY | |||
|
4174
Created by
admin on Wed Jul 05 22:38:33 UTC 2023 , Edited by admin on Wed Jul 05 22:38:33 UTC 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
SALT/SOLVATE -> PARENT |
|
||
|
TARGET -> AGONIST | |||
|
SALT/SOLVATE -> PARENT |
|
||
|
TARGET -> AGONIST |
Binding Assay
IC50
|
||
|
BINDER->LIGAND |
BINDING
|
||
|
SALT/SOLVATE -> PARENT |
|
||
|
BASIS OF STRENGTH->SUBSTANCE |
ASSAY (TITRATION)
EP
|
||
|
RACEMATE -> ENANTIOMER |
|
||
|
SALT/SOLVATE -> PARENT |
|
||
|
SALT/SOLVATE -> PARENT |
|
||
|
SALT/SOLVATE -> PARENT |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLITE -> PARENT |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
EP
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|
Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
---|---|---|---|---|---|---|
Volume of Distribution | PHARMACOKINETIC |
|
|
|||
Vdss | PHARMACOKINETIC |
|
|
|||
Biological Half-life | PHARMACOKINETIC |
|
|
|||